Results 241 to 250 of about 112,427 (348)
Cutaneous Symptoms of Cystic Fibrosis: A Narrative Review. [PDF]
Piątkiewicz M +4 more
europepmc +1 more source
Trafficking and potentiation of Nav1.7 and Nav1.8 channels are mediated by IQGAP1
Abstract figure legend IQGAP1 binds to the voltage‐gated Nav1.7 and Nav1.8 channels and TRPA1 channels in sensory neurons. Inflammatory mediators (IM), including PGE2 and TNFα, released during nerve injury and inflammation activate intracellular signalling messengers such as PKA, p38 MAPK and Cdc42 through their respective receptors.
Xuming Zhang +2 more
wiley +1 more source
Abstract figure legend Regulatory mechanisms such as alternative splicing, post‐translational modification, membrane trafficking, and protein interactions control channel gating, membrane abundance, and overall activity of PIEZO2. Proper regulation supports PIEZO2‐dependent proprioceptive, somatosensory, nociceptive, pruriceptive and interoceptive ...
Eunice I. Oribamise +2 more
wiley +1 more source
Organ-specific local cytokine release syndrome after anti-CD19 CAR-T therapy with salivary gland involvement: a case report, literature review, and a diagnostic alert for tocilizumab-associated cervical swelling. [PDF]
Maggi R +6 more
europepmc +1 more source
Latex allergy: a challenge for anaesthetists [PDF]
Demaegd, J, Herregods, Luc, Soetens, F
core +1 more source
Treatment of drug-induced hypersensitivity syndrome with cyclosporine
Guangjin Wang +4 more
openalex +1 more source
What's new? Errors in DNA double‐strand break (DSB) repair can lead to mutations, chromosomal instability, and ultimately cancer. Inhibitor of DNA‐binding 3 (ID3), a transcriptional repressor, is crucial to promoting DSB repair and helping maintain genome stability. Here, the authors investigated ID3 regulation of DNA repair via chromatin accessibility
Giuditta Della Corte +10 more
wiley +1 more source
A Case of Atypical Drug-Induced Hypersensitivity Syndrome While Taking Anti-Tubercular Drugs
Koji MAKINO +5 more
openalex +1 more source
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin +14 more
wiley +1 more source

